{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:08:49Z","timestamp":1766131729402,"version":"3.48.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euros.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:45:48Z","timestamp":1761414348000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and Safety of Xialiqi for the Treatment of Benign Prostatic Hyperplasia in a Randomized Trial"],"prefix":"10.1016","volume":"82","author":[{"given":"Feiya","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaozhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2696-5279","authenticated-orcid":false,"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.10.006_b0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.eururo.2024.04.031","article-title":"Bladder outlet obstruction relief and symptom improvement following medical and surgical therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review","volume":"86","author":"Creta","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.006_b0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1476-5381.2011.01332.x","article-title":"Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH)","volume":"163","author":"Ventura","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.euros.2025.10.006_b0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2174\/138161206776056010","article-title":"Inhibitors of 5\u03b1-reductase in the treatment of benign prostatic hyperplasia","volume":"12","author":"Tarter","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.euros.2025.10.006_b0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-4295(03)00045-1","article-title":"The role of dihydrotestosterone in benign prostatic hyperplasia","volume":"61","author":"Carson","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.euros.2025.10.006_b0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.juro.2013.09.059","article-title":"Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia","volume":"191","author":"Casab\u00e9","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.10.006_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.602","article-title":"The affinity and selectivity of \u03b1-adrenoceptor antagonists, antidepressants, and antipsychotics for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors","volume":"8","author":"Proudman","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.euros.2025.10.006_b0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ucl.2016.04.009","article-title":"Alpha-blockers for the treatment of benign prostatic hyperplasia","volume":"43","author":"Lepor","year":"2016","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euros.2025.10.006_b0040","doi-asserted-by":"crossref","first-page":"9474","DOI":"10.1073\/pnas.132552699","article-title":"Knockout of the \u03b11A\/C-adrenergic receptor subtype: the \u03b11A\/C is expressed in resistance arteries and is required to maintain arterial blood pressure","volume":"99","author":"Rokosh","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euros.2025.10.006_b0045","first-page":"9241","article-title":"Effects of Xialiqi capsules on rats with nonbacterial prostatitis","volume":"13","author":"Bai","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.euros.2025.10.006_b0050","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5367814","article-title":"The Effect of Xialiqi capsule on testosterone-induced benign prostatic hyperplasia in rats","volume":"2018","author":"Cai","year":"2018","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.euros.2025.10.006_b0055","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/antiox10101534","article-title":"Redox balance in male infertility: excellence through moderation\u2014\u201cm\u03ad\u03c4\u03c1\u03bf\u03bd \u1f04\u03c1\u03b9\u03c3\u03c4\u03bf\u03bd\u201d","volume":"10","author":"Symeonidis","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.euros.2025.10.006_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293682","article-title":"Diacerein provokes apoptosis, improves redox balance, and downregulates PCNA and TNF-\u03b1 in a rat model of testosterone-induced benign prostatic hyperplasia: a new non-invasive approach","volume":"18","author":"Rasheed","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.euros.2025.10.006_b0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13620-022-00228-3","article-title":"Oxidative stress biomarkers in dogs with benign prostatic hyperplasia","volume":"75","author":"Domoslawska","year":"2022","journal-title":"Ir Vet J"},{"key":"10.1016\/j.euros.2025.10.006_b0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000052361","article-title":"Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group","volume":"37","author":"van Kerrebroeck","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.006_b0075","first-page":"155","article-title":"Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group","volume":"29","author":"Chapple","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.006_b0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.juro.2013.10.074","article-title":"Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"191","author":"Roehrborn","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.10.006_b0085","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.10.006_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119369","article-title":"An integrated strategy for deciphering the action mechanism of emplastrum: prescription analysis- component identification- virtual screening and affinity testing in the case of Yaoshen Gao","volume":"342","author":"Feng","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.euros.2025.10.006_b0095","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.2174\/0113862073336172241220182220","article-title":"Verification of Qianlong Shutong formula in the treatment of benign prostatic hyperplasia","volume":"28","author":"Zhang","year":"2025","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.euros.2025.10.006_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1483864","article-title":"Efficacy and safety of oral Chinese patent medicine for benign prostatic hyperplasia: a network meta-analysis of randomized controlled trials","volume":"11","author":"Tang","year":"2024","journal-title":"Front Med"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325014296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325014296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:04:11Z","timestamp":1766131451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325014296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"alternative-id":["S2666168325014296"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.10.006","relation":{},"ISSN":["2666-1683"],"issn-type":[{"type":"print","value":"2666-1683"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Xialiqi for the Treatment of Benign Prostatic Hyperplasia in a Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}